Most advanced malaria vaccine candidates were initially designed without considering genetic diversity, resulting in poor protective efficacy as shown by FMP1/AS02A MSP1 or the AMA1 candidates that had limited vaccine allele representation in naturally circulating parasites, especially in Africa11, 35, 36. This evidence concerns the gene ATAD1 and malaria.